Výsledky vyhledávání - "L. M. Verhoef"

Patients’ perspectives towards biologic dose reduction in psoriasis: a qualitative study

Autor: L. S. van der Schoot, L. M. Verhoef, I. van Ee, F. P. A. H. van Oort, A. H. Pieterse, M. M. B. Seyger, E. M. G. J. de Jong, J. M. P. A. van den Reek

Publikováno v: Archives of Dermatological Research.

Dose reduction of biologics for psoriasis could contribute to more efficient use of these expensive medicines. Evidence on opinions of patients with psoriasis regarding dose reduction is sparse. The objective of this study was therefore to explore pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7c9a6840a035869b87360535094637a1
https://doi.org/10.1007/s00403-023-02566-w

Zobrazit plný text záznamu

OP0261 TREAT-TO-TARGET DOSE REDUCTION AND WITHDRAWAL STRATEGY OF TNF INHIBITORS IN PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS: A RANDOMIZED CONTROLLED NON-INFERIORITY TRIAL

Autor: C. Michielsens, N. den Broeder, F. van den Hoogen, E. Mahler, S. Teerenstra, D. van der Heijde, L. M. Verhoef, A. den Broeder

Publikováno v: Annals of the Rheumatic Diseases. 81:172-173

BackgroundTumour Necrosis Factor inhibitors (TNFi) are effective in Psoriatic Arthritis (PsA) and axial SpondyloArthritis (axSpA), but are associated with a somewhat increased infection risk, patient burden, and high costs. Treat-to-target (T2T) tape

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f5174b5e1144434999b3d077a0db5ad4
https://doi.org/10.1136/annrheumdis-2022-eular.1430

Zobrazit plný text záznamu

POS0638 RECOMMENDATIONS FOR COST-EFFECTIVE USE OF BIOLOGICAL AND TARGETED SYNTHETIC DMARDS IN INFLAMMATORY ARTHRITIS: RESULTS FROM AN INTERNATIONAL DELPHI STUDY

Autor: C. Van der Togt, B. Van den Bemt, D. Aletaha, R. Alten, K. Chatzidionysiou, J. Galloway, J. Isaacs, D. Mulleman, P. Verschueren, A. Vulto, P. Welsing, L. M. Verhoef, A. Den Broeder

Publikováno v: Annals of the Rheumatic Diseases. 81:588.2-588

BackgroundBiological and targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) are effective treatments for rheumatoid arthritis (RA), psoriatic arthritis (PsA) and spondyloarthritis (SpA), but associated with high costs. Therefore, v

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3036cbbbae53e2321dbc0b3871f1365a
https://doi.org/10.1136/annrheumdis-2022-eular.433

Zobrazit plný text záznamu

OP0305 THE EMERGING EULAR NETWORK (EMEUNET) PEER-REVIEW MENTORING PROGRAM: TEN YEARS OF INITIATIVE

Autor: L. M. Verhoef, A. Vivekanantham, A. Berti, E. C. Bolek, H. T. Smeele, M. Oztas, S. Shoop-Worrall, S. S. Zhao, F. Rivellese, K. Lauper, S. Piantoni

Publikováno v: Annals of the Rheumatic Diseases. 81:202.1-203

BackgroundIn 2012, the Emerging EULAR (European Alliance of Associations for Rheumatology) Network (EMEUNET) started a mentoring program in collaboration with the editorial board of top-leading journals in rheumatology, the Annals of the Rheumatic Di

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::56ae056348669433cba4b6f79d812b8c
https://doi.org/10.1136/annrheumdis-2022-eular.1877

Zobrazit plný text záznamu

POS0652 LONG-TERM EFFECTIVENESS OF ULTRA-LOW DOSES OF RITUXIMAB IN RHEUMATOID ARTHRITIS

Autor: N. Den Broeder, L. M. Verhoef, Y. A. De Man, M. R. Kok, R. M. Thurlings, W. Van der Weele, B. Van den Bemt, F. Van den Hoogen, A. Van der Maas, A. Den Broeder

Publikováno v: Annals of the Rheumatic Diseases. 81:597.2-598

BackgroundThe optimal rituximab (RTX) dose for the treatment of rheumatoid arthritis remains unclear. RTX treatment of 1000mg per 6 months and 2000mg per 6 months were shown to be similarly efficacious (1). The REDO trial showed comparable the 6-mont

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::401b9dddab9c5e268da221004f73fc6e
https://doi.org/10.1136/annrheumdis-2022-eular.2903

Zobrazit plný text záznamu

POS1561-HPR HEALTH CARE PROVIDERS’ PERSPECTIVE ON CONTINUATION VERSUS TEMPORARY INTERRUPTION OF IMMUNOMODULATORY AGENTS IN CASE OF AN INFECTION: AN INTERVIEW STUDY

Autor: M. Opdam, J. E. Vriezekolk, A. Den Broeder, L. M. Verhoef

Publikováno v: Annals of the Rheumatic Diseases. 81:1126.2-1127

BackgroundImmunomodulatory agents (IA) are often used in the treatment of immune mediated inflammatory diseases (IMIDs). The use of some of these IA is associated with a slightly increased infection risk (1), which raises concerns especially during t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b26bab329bc0bc9f92f407348e22491a
https://doi.org/10.1136/annrheumdis-2022-eular.1258

Zobrazit plný text záznamu

POS0639 PHARMACOKINETIC BOOSTING TO ENABLE A ONCE-DAILY REDUCED DOSE OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS

Autor: C. Van der Togt, L. M. Verhoef, B. Van den Bemt, N. Den Broeder, R. Ter Heine, A. Den Broeder

Publikováno v: Annals of the Rheumatic Diseases. 81:588.1-589

BackgroundTofacitinib is an effective drug for rheumatoid arthritis (RA) and psoriatic arthritis (PsA). As tofacitinib is metabolized by the CYP3A4-enzyme, the manufacturer recommends to reduce the dose with 50% when combined with CYP3A4-inhibitors.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7e4b58f069c88bbabad6a8ff10819598
https://doi.org/10.1136/annrheumdis-2022-eular.1007

Zobrazit plný text záznamu

POS0646 NON-MEDICAL SWITCHING FROM TOCILIZUMAB TO SARILUMAB IN RHEUMATOID ARTHRITIS PATIENTS WITH LOW DISEASE ACTIVITY

Autor: N. Den Broeder, A. Den Broeder, L. M. Verhoef, F. Van den Hoogen, A. Van der Maas, B. Van den Bemt

Publikováno v: Annals of the Rheumatic Diseases. 81:593.2-594

BackgroundTocilizumab (TCZ) and sarilumab (SRL) are IL6-receptor antagonists registered for the treatment of rheumatoid arthritis (RA). Data from extension of the ASCERTAIN trial showed that patients responding to blinded intravenous (IV) TCZ rarely

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::03be81341cde95b30e41404267b18fe0
https://doi.org/10.1136/annrheumdis-2022-eular.2156

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání